A review of indicators for heart failure in people with hypertension

Abstract

High sensitivity, specificity, repeatability, cost-effectiveness, and incremental predictive or diagnostic efficacy over conventional risk factors or tests are required of biomarkers. Only a few biomarkers have been shown to accurately predict heart failure (HF) in hypertensive patients, despite several studies looking at these biomarkers. This article compiles information from a number of studies on potential biomarkers of HF in hypertensive patients, including serum uric acid (SUA), interleukins, monocyte chemoattractant protein one (MCP1), cardiotrophin-1 (CT-1), carboxy-terminal propeptide of procollagen type I (PICP), type I collagen telopeptide (CITP), and N-terminal propeptide of type III procollagen (PIIINP Early implementation of efficient preventive measures may arise from patient identification of elevated risk for hypertensive heart disease.In order to identify patients for whom earlier or more aggressive action can enhance clinical outcomes, it is necessary to develop newer biomarkers that can improve risk prediction.